Skip to content
Magazine
Saturday, August 2, 2025
SUBSCRIBE
  • About Us
  • Belgium News
    • Belgium Police News
    • Brussels News
  • EU Institutions News
    • European Commission News
    • European Parliament News
    • European Council News
  • Europe News
  • World News
  • Belgium Business News
  • Culture and Society News
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
  • About Us
  • Belgium News
    • Belgium Police News
    • Brussels News
  • EU Institutions News
    • European Commission News
    • European Parliament News
    • European Council News
  • Europe News
  • World News
  • Belgium Business News
  • Culture and Society News
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
SUBSCRIBE

UK first to approve BioNTech Pfizer vaccine

Sophia Akram by Sophia Akram
2 December 2020
in Europe News
A syringe and two bottles of COVID-19 vaccine on UK map. Covid vaccination in Great Britain. 3d illustration

A syringe and two bottles of COVID-19 vaccine on UK map. Covid vaccination in Great Britain. 3d illustration

London (Brussels Morning) In a world-first, the UK has approved a vaccine developed by the German-American duo BioNTech and Pfizer. Rollout could commence as early as next week.

The race to develop a vaccine to immunise people against COVID-19 has ensued since the beginning of 2020 with around 200 candidates in progress. Several have reported high efficacy, including a drug developed by Moderna and Oxford University and AstraZeneca.

Ministers have called the prospect of the vaccine a “ray of hope” although administering it at a national level will remain challenging.

The Medicines and Healthcare products Regulatory Agency (MHRA), Britain’s regulatory authority on the use of new drugs, has stamped its approval on the vaccine just 23 days after final-stage clinical trial results were published.

UK Prime Minister Boris Johnson called the news “Fantastic”, but cautioned against over-excitement.

“At this stage it is very, very important that people do not get their hopes up too soon about the speed with which we will be able to roll out this vaccine”, he said.

Administration of the vaccine will take place in stages prioritising the most vulnerable as follows:

  • Care home residents and their carers.
  • Over 80s and frontline health and social care workers.
  • Over 75s.
  • Those 70 years and older and the clinically vulnerable.
  • Those 65s.
  • Anyone aged 16 to 64 with underlying health conditions with high risk of serious illness or mortality.
  • Over 60s.
  • Over 55s.
  • Over 50s.

The US and EU are also looking at the vaccine’s trial data but are yet to approve its use.

The EU regulator has defended its own longer procedures as more robust and appropriate.

Celebratory tones from among Britain’s political circles have also faced rebuke.

Germany’s ambassador to Britain Andreas Michaelis said, “I really don’t think this is a national story. In spite of the German company BioNTech having made a crucial contribution, this is European and transatlantic”.

MHRA has insisted, “No corners have been cut.

“Safety is our watchword”, said head of MHRA, June Raine.

The UK has ordered 40 million doses of the Pfizer vaccine to cover a third of the population. Those eligible to be first in line will likely be notified by letter.

Related News:

  • EMA approves Pfizer/BioNTech vaccine
  • Pfizer vaccine for COVID-19 90 percent there
  • Vaccine export bans won’t help the fight against Covid-19, says Pfizer
  • EC adapts COVID-19 vaccine agreement with Pfizer
Tags: BritanCoronavirus vaccineNews
Next Post

Biden and Kerry’s Global Climate Challenge

Latest post

EU-elections-UK

EU elections: UK looks on from the “outside”

1 year ago
Galeries-Royales-Saint-Hubert

What Makes Galeries Royales Saint-Hubert an “Institution”?

1 year ago

Most Read

    Follow Brussels Morning
    Facebook Twitter Youtube Linkedin

    Browse Important News

    Belgium News
    Brussels News
    Culture and Society News
    Economy News
    EU Institutions News
    European Commission News
    European Council News
    European Parliament News
    Europe News
    Health And Fitness News
    Southeast Europe News
    Sustainable Perspective
    World News
    Diplomacy News
    US Elections News

    About Us

    Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

    More Info

    • About Us
    • Advertise With Us
    • Contact Us
    • Cookies Policy

    Join Our Newsletter

    Brussels Morning Newspaper – All Rights Reserved © 2024

    No Result
    View All Result
    • Home
    • About Us
    • Belgium News
      • Belgium Police News
      • Brussels News
    • Brussels Bubble
      • European Parliament News
      • European Commission News
      • European Council News
    • Wider Europe
      • Member States
    • World News
    • Business & Society
    • Europe With Transparency
    • Culture & Society
    • Policy Talks
      • Place de la Bourse
      • The Macro-Economist
      • Sustainable Perspective
      • Ambassador’s Corner
      • The American Angle
      • Southeast Europe
    • Print Magazine

    Brussels Morning Newspaper - All Rights Reserved © 2020

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT